Clinical study demonstrates improved outcomes in acute myeloid leukemia using pharmacokinetic-guided busulfan and T-cell depletion, indicating enhanced transplant safety.
Pharmacokinetic‐based busulfan administration improves the therapeutic window and in vivo T‐cell depletion with antilymphocyte globulins reduces graft‐versus‐host disease incidence. In this study, both were used, showing an improvement of clinical outcomes in patients with acute myeloid leukemia.
No takes yet. Share an insight, caveat, or question.
Bono et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: